Nabholtz JM - Search Results

1

Ocular toxicity and cancer chemotherapy. A review.

al-Tweigeri T, Nabholtz JM, Mackey JR. al-Tweigeri T, et al. Among authors: nabholtz jm. Cancer. 1996 Oct 1;78(7):1359-73. doi: 10.1002/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.CO;2-G. Cancer. 1996. PMID: 8839540 Review.

2

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noël DR, Al-Tweigeri T, Tonkin K, North S, Azli N, Riva A. Nabholtz JM, et al. J Clin Oncol. 2001 Jan 15;19(2):314-21. doi: 10.1200/JCO.2001.19.2.314. J Clin Oncol. 2001. PMID: 11208821 Clinical Trial.

3

Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J. Nabholtz JM, et al. Expert Opin Pharmacother. 2000 Jan;1(2):187-206. doi: 10.1517/14656566.1.2.187. Expert Opin Pharmacother. 2000. PMID: 11249542 Review.

4

Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.

Nabholtz JM, Smylie M, Mackey JR, Noel D, Paterson AH, al-Tweigeri T, Au D, Sansregret E, Delorme F, Riva A. Nabholtz JM, et al. Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):37-41. Oncology (Williston Park). 1997. PMID: 9364541 Clinical Trial.

5

Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature.

Mackey JR, Desai S, Larratt L, Cwik V, Nabholtz JM. Mackey JR, et al. Among authors: nabholtz jm. Bone Marrow Transplant. 1997 May;19(9):939-42. doi: 10.1038/sj.bmt.1700759. Bone Marrow Transplant. 1997. PMID: 9156270

6

The academic global virtual concept in clinical cancer research and its application to breast cancer: The Breast Cancer International Research Group.

Nabholtz JM, Lindsay MA, Hugh J, Mackey J, Smylie M, Au HJ, Tonkin K, Allen M. Nabholtz JM, et al. Semin Oncol. 1999 Jun;26(3 Suppl 8):4-8. Semin Oncol. 1999. PMID: 10403467

7

Autologous bone marrow support and bone disease in metastatic breast cancer.

Nabholtz JM, al-Tweigeri T, Jacquelin N, Venner PM. Nabholtz JM, et al. Can J Oncol. 1995 Dec;5 Suppl 1:33-9. Can J Oncol. 1995. PMID: 8853522 Review.

8

Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.

Nabholtz JM, Smylie M, Mackey J, Paterson A, Noel D, al-Tweigeri, Janowska A, Delorme F, Riva A. Nabholtz JM, et al. Oncology (Williston Park). 1997 Jun;11(6 Suppl 6):25-7. Oncology (Williston Park). 1997. PMID: 9213324 Clinical Trial.

9

Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.

Nabholtz JM, Tonkin K, Smylie M, Mackey J, Janowska-Wieczorek A. Nabholtz JM, et al. Semin Oncol. 1999 Feb;26(1 Suppl 3):10-6. Semin Oncol. 1999. PMID: 10203265 Review.

10

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J. Nabholtz JM, et al. Clin Breast Cancer. 2002 Oct;3(4):268-75. doi: 10.3816/CBC.2002.n.030. Clin Breast Cancer. 2002. PMID: 12425755 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page